LUNAC Therapeutics

📍 Leeds, United Kingdom👥 4 employees💰 Last funded Aug 2023
Research🌐 lunactherapeutics.com
Website LinkedIn
LUNAC Therapeutics is a spin out from the University of Leeds, UK and is pursuing the discovery of next generation oral anticoagulant therapies with a reduced risk of causing bleeding compared to current treatments. The business is founded on IP generated by Professor Helen Philippou (Professor of Translational Medicine in the Faculty of Medicine and Health at the University of Leeds) and Dr Richard Foster (Associate Professor at the University of Leeds), built on a decade of academic research into FXIIa in association with some of the world’s leading supporters of scientific and medical research, including the Wellcome Trust, British Heart Foundation and the UK’s Medical Research Council.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in LUNAC Therapeutics?
LUNAC Therapeutics has 1 investors on record on gritt.io.
When did LUNAC Therapeutics last raise funding?
The most recent investment in LUNAC Therapeutics recorded on gritt.io was in August 2023.
What industry is LUNAC Therapeutics in?
LUNAC Therapeutics operates in Research. Find similar Research investors on gritt.io.
Where is LUNAC Therapeutics based?
LUNAC Therapeutics is headquartered in Leeds, United Kingdom.